臺灣博碩士論文加值系統

巴金森氏病(簡稱巴病)是僅次於阿茲海默症最常見的神經退化性疾病。其致病機轉是由於位在中腦黑質的突觸前多巴胺神經元的退化，造成投射至紋狀體的多巴胺減少而導致運動障礙。座落在染色體12q12上，由51個exons組成的leucine-rich repeat kinase 2 (簡稱LRRK2)基因，是顯性遺傳巴病最常見的致病基因，也是目前和傳統老年型巴病病患最相關的一個基因。在漢人的基因相關性研究(genetic association study)中發現，LRRK2 G2385R變異是漢人中獨特的巴病基因危險因子。在臨床表現上，帶有LRRK2 G2385R變異的巴病患者和典型偶發性巴病患者幾乎無法區分。在體外的細胞實驗中發現，在有外來毒物的環境下G2385R變異會加速細胞凋亡。病理的研究顯示運動障礙症狀出現時，約有60%的多巴胺神經元已凋亡，由此可知運動前期的診斷(premotor diagnosis)對於巴病的預防以及神經保護藥物的發展甚為重要。病理研究亦顯示巴病神經元的退化起始於延腦與顱底的嗅覺構造，而在臨床上嗅覺測驗工具UPSIT可檢測出早期的嗅覺功能異常。再者，運用多巴胺系統核子影像工具如18F-dopa PET，可發現多巴胺系統在影像上所呈現的變化要比運動障礙症狀的出現提早4-6年。此外，更有學者指出縱使臨床尚未出現運動障礙的症狀，穿顱超音波影像上出現的黑質hyperechogenicity可作為多巴胺系統的易感標記。基於以上的備景說明，我們進行此ㄧ病例對照研究(case-control study)。研究之目在於，以帶有漢人族群特有巴病的基因危險因子LRRK2 G2385R變異的無症狀帶因者為對象，評估嗅覺測驗、多巴胺系統核子影像18F-dopa PET和黑質之穿顱超音波影像在巴金森氏病運動前期診斷的價值。
本研究中共收錄了526健康受試者進行基因篩檢，其中有24位是G2385R變異的帶因者 (男性6位，女性18位)，占所有健康志願者的4.6%。在帶因者中符合納入條檢者有15位，並同時收錄15位年齡與性別相符之非帶因者作為對照組。本研究發現華人特有巴病危險因子LRRK2 G2385R變異在巴病的運動前期可能導致多巴系統的退化。同時，也發現多巴胺核子影像工具18F-dopa PET的被殼指標不論在巴病的診斷或是運動前期的運用上都是較為敏感的指標。和對照組相較，在G2385R變異帶因者的運動前期，並未發現明顯的嗅覺異常或代表鐵質代謝異常的黑質hyperechogenicity的情形，暗示前述兩者運動前期的臨床表現可能與LRRK2 G2385R變異無關，亦獨立於多巴胺系統之外。此外，在G2385R帶因者中，某些在運動前期已出現多巴胺系統退化現象、嗅覺異常或是帶有黑質hyperechogenicity的受試者，則需進ㄧ步追蹤日後是否出現巴金森氏病的症狀，以期能早期治療。

Parkinson’s disease(PD) is a relentlessly progressive neurodegenerative disorder caused by loss of dopaminergic neurons in the substantia nigra(SN). It is characterized by motor symptoms of bradykinesia, rest tremor and rigidity. Mutations in the gene leucine-rich repeat kinase 2 (LRRK2), located on chromosome 12p11.2-q13, are the most frequent causes of familial autosomal dominant PD. Recently genetic association studies identified LRRK2 G2385R variant is a common risk polymorphism for sporadic PD in the Chinese population. In vitro studies of transfected cells have proved that G2385R variant iss more vulnerable to oxidative stress and associated with a higher rate of apoptosis.
Pathological studies have shown that at the time when PD motor symptoms appear, a significant amount with approximate 60% of dompaminergic neurons in the SN has already occurred. In the clinical aspects, hyposmia is considered as premotor sign of PD. Degeneration in the olfactory system has been also proved pathologically to be early in the stage of this degenerative disease. Moreover, based on in vivo PET and SPECT imaging of the dopaminergic system, the onset of dopaminergic neuronal loss antedates the motor symptoms of PD by approximately 4 to 6 years. Recently increased echogenicity of SN detected by transcranial sonography has been related to a functional impairment of the nigrostriatal system. It has also been proved to be a susceptibility marker for the development nigral injury that can be detected early in life prior to the onset of motor symptoms. These facts signify the importance of early diagnosis of PD in the premotor phase, in which neuroprotective measures can possibly intervene.
With this background, we conducted this case-control cohort study in a hospital based cohort. We intended to evaluate various tools of premotor diagnosis with olfactory test, 18F-dopa PET and transcranial sonography of SN in the healthy subjects carrying LRRK2 G2385R variant, which has been proved to be specific for ethnic Han Chinese population.
526 healthy subjects were recruited from the PD center of National Taiwan University hospital for genetic screening of LRRK2 G2385R polymophism. Twenty four of them are G2385R variants. The prevalence rate of G2385R polymophism in our study group is 4.6%, which is similar to previous studies. Fifteen G2385R variants fulfilling the criteria of our study were then included for premotor diagnosis study. Meanwhile, fifteen aged and sex matched non-variants were included as control group. In the study of 18F-dopa PET, G2385R variants manifested a non-significant tendency to have decreased 18F-dopa uptake in the striatum, particularly in bilateral putamens. Our study has also proved that putaminal indicator of 18F-dopa PET imaging is a more sensitive indictor than the caudate indicator in terms of both clinical diagnosis and premotor diagnosis of PD. Furthermore, the G2385R variants did not show hyposmia or SN hyperechogenicity in comparison to the control group. It suggested that these two aforementioned premotor signs of PD seemed not related to LRRK G2385R polymophism. We should further follow particular subjects in this study, who presented with hyposmia, dopaminergic dysfunction shown by 18F-dopa PET, or SN hyperechoenicity to see if motor symptoms merge in the future and take in-time therapeutic intervention if PD is once diagnosed.

中文摘要………………………………………….……… I
英文摘要………………………………………………. III

第一章 緒論
第一節 巴金森氏病簡介………………………………. 1
第二節 巴金森氏病的遺傳學……………………….… 3
第三節 巴金森氏病的運動前期與診斷工具……….… 7
第四節 研究目的與假說……….……………………. 12

第二章 研究方法
第一節 受試者…………………………………… …. 13
第二節 研究工具…………………………………… . 14
第三節 研究流程…………………………………… . 19
第四節 統計分析…………………………………… . 20

第三章 研究結果
第一節 18F- dopa PET常模之建立 …………………. 21
第二節 LRRK2 G2385R帶因者運動前期診斷之結果…. 23

第四章 討論
第一節 18F- dopa PET在巴病診斷上的運用 ………. 26
第二節 LRRK2 G2385R帶因者巴病運動前期診斷……. 28
第三節 本研究的限制…… …………………..……… 35
第四節 本研究貢獻與未來的展望.………..………… 36

論文英文簡述（Summary）……………… …....……. 38
參考文獻…………………………………………………. 55
附錄
附錄一 受試者同意書…………………………………. 82
附錄二 巴病運動障礙量表（UPDRS）……...………. 87
附錄三 簡易智能評估 （MMSE）………...…………. 88
附錄四 嗅覺測試問卷…………………………………. 89

An XK, Peng R, Li T, Burgunder JM, Wu Y, Chen WJ, Zhang JH, Wang YC, Xu YM, Gou YR, Yuan GG, Zhang ZJ. LRRK2 Gly2385Arg variant is a risk factor of Parkinson''s disease among Han-Chinese from mainland China. European Journal of Neurology 2008 Mar; 15:301-5
Akbas N, Hochstrasser H, Deplazes J, Tomiuk J, Bauer P, Walter U, Behnke S, Riess O, Berg D. Screening for mutations of the HFE gene in Parkinson''s disease patients with hyperechogenicity of the substantia nigra. Neuroscience Letters. 2006 Oct; 407:16-9
Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson''s disease visualized by transcranial color-coded real-time sonography. Neurology 1995 Jan; 45:182-4
Berg D, Seifker C, Becker G. Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. Journal of Neurology 2001 Aug; 248:684-89
Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Archives of Neurology 2002 Jan; 59:999-1005.
Berg D, Schweitzer K, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brussel T, Schulte C, Maass S, Nagele T. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson’s disease. Brain 2005 Dec; 128:3000-11
Berg D. Transcranial ultrasound as a risk marker for Parkinson''s disease. Movement Disorders. 2009; 24 Suppl 2:S677-83. Review.
Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003 Jan; 299:256-9

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging 2003 Mar-Apr; 24:197-211
Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Annals of Neurology 1990 Oct; 28:547-55
Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, Chen ZY, Liou HH. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001 Nov; 57:1679-86.
Damier P, Hirsch EC, Agid Y, Graybiel AM. The substaintia nigra of the human brain. II. Patterns of loss of dopamine containing neurons in Parkinson’s disease. Brain 1999 Aug; 122:1437-48
de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet of Neurology 2006 Jun; 5:525-35. Review.
Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? Journal of Neuropathology and Experimental Neurology. 2002 May; 61:413-26.
DeJesus OT, Endres CJ, Shelton SE, et al. Evaluation of fluorinated m-tyrosine analogs as PET imaging agent of dopamine nerve terminals: comparison with 6-fluoroDOPA. Journal of Nuclear Medicine 1997 Apr; 38:630-636.
Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, Margouleff C, Eidelberg D. Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: ratio method versus graphical approach. Journal of Nuclear Medicine 2002 Oct; 43:1324-30
Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V; Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet 2005 Jan; 365:412-5
Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohé CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson''s disease risk in Taiwan. Neurogenetics 2006 Jul; 7:133-8.
Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984 Feb; 94:176-8.
Doty RL, Shaman P, Applebaum SL, Giberson R, Siksorski L, Rosenberg L. Smell identification ability: changes with age. Science 1984 Dec; 226:1441-3
Doty RL, Frye RE, Agrawal U. Evaluation of the internal consistency and reliability of the fractionated and whole University of Pennsylvania Smell Identification Test (UPSIT). Perception and Psychophysics 1989 May; 45:381-4
Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 1992 Feb; 55:138-42
Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson''s disease. Neurology 1993 May; 43:962-5.
Doty RL, McKeown DA, Lee WW and Shaman P. A study of the test-retest reliability of ten olfactory tests. Chemical Senses 1995 Dec; 20:645-56
Doty RL. Office procedures for quantitative assessment of olfactory function. American Journal of Rhinology. 2007 Jul-Aug; 21:460-73. Review.
Erik F. J. de Vries, Gert Luurtsema, Michael Brüssermann, Philip H. Elsinga, Willem Vaalburg. Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]fluoro-L-DOPA. Applied Radiation and Isotopes 1999 Jan; 51:389-94
Fahn S, Elton RL and members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors, Recent developments in Parkinson’s disease, Floral Park, NJ: Macmillan Healthcare Information, 1987, pp. 153-63
Farrer MJ, Stone JT, Lin CH, Dächsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM. Lrrk2 G2385R is an ancestral risk factor for Parkinson''s disease in Asia. Parkinsonism Related Disorders 2007 Mar; 13: 89-92
Felletschin B, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Sommer U, Zeiler B, Becker G, Riess O, Berg D. Screening for mutations of the ferritin light and heavy genes in Parkinson''s disease patients with hyperechogenicity of the substantia nigra. Neuroscience Letters. 2003 Nov; 352:53-6.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975 Nov; 12:189-98.
Forno LS. Neuropathology of Parkinson''s disease. Journal of Neuropathology and Experimetal Neurology. 1996 Mar; 55:259-72. Review
Gaig C, Tolosa E. When does Parkinson''s disease begin? Movement Disorders. 2009;24 Suppl 2:S656-64. Review.
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry 1988 Jan; 51:745-52
Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW. A common LRRK2 mutations in idiopathic Parkinson’s disease. Lancet 2005 Jan; 365: 415-6
Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson’s disease and striatonigral degeneration. Annals of Neurology 1989 Dec; 26:766-70
Hagenah JM, König IR, Becker B, Hilker R, Kasten M, Hedrich K, Pramstaller PP, Klein C, Seidel G. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. Journal of Neurology. 2007 Oct; 254:1407-13.
Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Zeiler B, Bornemann A, Pahnke J, Becker G, Riess O, Berg D. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology. 2004 Nov 23;63:1912-7.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967 May; 17: 427-42
Huang YW, Jeng JS, Tsai CF, Chen LL, Wu RM. Transcranial Imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson’s disease. Movement Disorders 2007 Mar; 22:550-5
Ito K, Morrish PK, Rakshi JS, et al. Statistical parametric mapping with F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson’s disease. Journal of Neurology Neurosurgery & Psychiatry 1999 Jun; 66:754-758
Ishikawa T, Dhawan V, Chaly T, et al. Clinical significance of striatal DOPA decarboxylase activities in Parkinson’s disease. Journal of Nuclear Medicine 1996 Feb; 37: 216-22
Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson''s disease. Neurology. 1996 Dec;47(6 Suppl 3):S161-70. Review.
Jiang RS, Lin TK, and Hsu CY. The application of the University of Pennsylvania Smell Identification Test and Cross-Culture Smell Identification Test in Taiwan. Journal of Taiwan Otolaryngolological Head and Neck Surgery 2002; 37:431-6,
Jiang RS, Su MC, Liang KL, Shiao JY, Wu SH, Hsin CH. A pilot study of a traditional Chinese version of the University of Pennsylvania Smell Identification Test for application in Taiwan. American Journal Rhinology and Allergy. 2010 Jan-Feb;24:45-50.
Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson''s disease: a critical analysis of alpha-synuclein staging. Neuropathology and Applied Neurobiology. 2008 Jun; 34:284-95.
Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DT, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Annals of Neurology 2002 Dec; 52:849-53
Khan NL, Scherfler C, Graham E, Bhatia KP, Quinn NP, Lees AJ, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 2005 Jan; 64:134-6
Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson''s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005 Dec; 128: 2786-2796
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998 Apr; 392:605-8
Klein C, Lohmann-Hedrich K. Impact of recent genetic findings in Parkinson''s disease. Current Opinion in Neurology. 2007 Aug; 20:453-64
Laihinen A, Ruottinen H, Rinne JO, Haaparanta M, Bergman J, Solin O, et al. Risk for Parkinson’s disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. Journal of Neurology 2000 Apr; 247 (Suppl 2:II): 110-3
Lin CH, Tzen KY, Yu CY, Tai CH, Farrer MJ, Wu RM. LRRK2 mutation in familial Parkinson’s disease in a Taiwanese population: clinical, PET and functional studies. Journal Biomedical Sciences 2008 Sep; 15:661-7
Markopoulou K, Larsen KW, Wszolek EK, Denson MA, Lang AE, Pfeiffer RF, Wszolek ZK. Olfactory dysfunction in familial parkinsonism. Neurology 1997 Nov; 49:1262-7
Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ. Lrrk2 pathogenic substitutions in Parkinson''s disease. Neurogenetics 2005 Dec; 6:171-7
Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson''s disease: protein domains and functional insights. Trends in Neurosciences 2006 May; 29:286-93
Matsumine H. A loss-of-function mechanism of nigral neuron death without Lewy body formation: autosomal recessive juvenile parkinsonism (AR-JP). Journal of Neurology 1998 Nov; 245:10-4.
Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, Suda K, Mizuno Y. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998 Sep; 51:890-2.
Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. Journal Neurology, Neurosurgery & Psychiatry 1998 Mar; 64:314-9
Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation of Parkinson’s disease. Annals of Neurology 2001 Aug; 50:181-87
Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, Tan EK, Dawson VL, Dawson TM, Yu F, Lim KL. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. Journal of Neuroscience. 2009 Sep;29:11257-62.
Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8 –linked Parkinson’s disease. Neuron 2004 Nov; 44:595-600
Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC; Parkinson Study Group-PROGENI Investigators. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson''s disease. Movement Disorders. 2006 Dec;21:2257-60.
Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta of Neuropathology. 2008 Apr;115:399-407.
Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECh, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Annals of Neurology 2004 Aug; 56:173-181
Ruprecht-Dörfler P, Berg D, Tucha O, Benz P, Meier-Meitinger M, Alders GL, Lange KW, Becker G. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease. Neuroimage 2003 Feb; 18:416-22
Sawle GV, Wroe SJ, Lees AJ, Brooks DJ, Frackowiak RS. The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred. Annals of Neurology 1992 Nov; 32:609-17
Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996 Feb;46:388-93.
Schweitzer KJ, Brüssel T, Leitner P, Krüger R, Bauer P, Woitalla D, Tomiuk J, Gasser T, Berg D. Transcranial ultrasound in different monogenetic subtypes of Parkinson''s disease. Journal of Neurology. 2007 May;254:613-6.
Siderowf A, Stern MB. Update on Parkinson’s disease. Annals of Internal Medicine 2003 Apr;138:651-8.
Smith TF, Gaitatzes C, Saxena K, Neer EJ. The WD repeat: a common architecture for diverse functions. Trends Bichemical Sciences 1999 May; 24:181-5
Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, Kimura H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Annals of Neurology. 1993 Sep; 34: 324-30.
Stern MB. The preclinical detection of Parkinson''s disease: ready for prime time? Annals of Neurolology. 2004 Aug; 56:169-71.
Stoessl AJ. Positron emission tomography in premotor Parkinson''s disease. Parkinsonism Related Disorders. 2007;13 Suppl 3:S421-4. Review.
Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, Fook-Chong S, Tang S, Chua E, Yuen Y, Tan L, Pavanni R, Wong MC, Kolatkar P, Lu CS, Bonifati V, Liu JJ. The LRRK2 Gly2385Arg variant is associated with Parkinson''s disease: genetic and functional evidence. Human Genetics 2007 Feb; 120: 857-63
Tan EK, Peng R, Teo YY, Tan LC, Angeles D, Ho P, Chen ML, Lin CH, Mao XY, Chang XL, Prakash KM, Liu JJ, Au WL, Le WD, Jankovic J, Burgunder JM, Zhao Y, Wu RM. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Human Mutation. 2010 May;31:561-8.

Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson''s disease. Journal of Nuclear Medicine 1998 Jul; 39:1143-8.
Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC, Wolters EC.Loss of olfaction in de novo and treated Parkinson''s disease: possible implications for early diagnosis. Movement Disorders. 2001 Jan;16:41-6.
Tolosa E, Gaig C, Santamaría J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology. 2009 Feb;72(7 Suppl):S12-20. Review.
Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 2004 Sep; 304:1158-60
Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 2004 Nov; 44: 601-7
Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes. Neurology 2003 Jan; 60:74-7